

Patrícia M A Silva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2727480/publications.pdf>

Version: 2024-02-01

27
papers

681
citations

687363

13
h-index

580821

25
g-index

27
all docs

27
docs citations

27
times ranked

903
citing authors

#	ARTICLE	IF	CITATIONS
1	BUB3, beyond the Simple Role of Partner. <i>Pharmaceutics</i> , 2022, 14, 1084.	4.5	7
2	Navitoclax Enhances the Therapeutic Effects of PLK1 Targeting on Lung Cancer Cells in 2D and 3D Culture Systems. <i>Pharmaceutics</i> , 2022, 14, 1209.	4.5	3
3	The Mad2-Binding Protein p31comet as a potential target for human cancer therapy. <i>Current Cancer Drug Targets</i> , 2021, 21, 401-415.	1.6	1
4	Antagonizing the spindle assembly checkpoint silencing enhances paclitaxel and Navitoclax-mediated apoptosis with distinct mechanistic. <i>Scientific Reports</i> , 2021, 11, 4139.	3.3	12
5	Tetracyclic Thioxanthene Derivatives: Studies on Fluorescence and Antitumor Activity. <i>Molecules</i> , 2021, 26, 3315.	3.8	2
6	Second-Generation Antimitotics in Cancer Clinical Trials. <i>Pharmaceutics</i> , 2021, 13, 1011.	4.5	26
7	Generation of Two Paclitaxel-Resistant High-Grade Serous Carcinoma Cell Lines With Increased Expression of P-Glycoprotein. <i>Frontiers in Oncology</i> , 2021, 11, 752127.	2.8	9
8	BP-M345, a New Diarylpentanoid with Promising Antimitotic Activity. <i>Molecules</i> , 2021, 26, 7139.	3.8	8
9	A Pyranoxanthone as a Potent Antimitotic and Sensitizer of Cancer Cells to Low Doses of Paclitaxel. <i>Molecules</i> , 2020, 25, 5845.	3.8	6
10	Three-Dimensional Spheroids as In Vitro Preclinical Models for Cancer Research. <i>Pharmaceutics</i> , 2020, 12, 1186.	4.5	185
11	Chalcone derivatives targeting mitosis: synthesis, evaluation of antitumor activity and lipophilicity. <i>European Journal of Medicinal Chemistry</i> , 2019, 184, 111752.	5.5	32
12	Discovery of a New Xanthone against Glioma: Synthesis and Development of (Pro)liposome Formulations. <i>Molecules</i> , 2019, 24, 409.	3.8	14
13	Spindly and Bub3 expression in oral cancer: Prognostic and therapeutic implications. <i>Oral Diseases</i> , 2019, 25, 1291-1301.	3.0	17
14	New Alkoxy Flavone Derivatives Targeting Caspases: Synthesis and Antitumor Activity Evaluation. <i>Molecules</i> , 2019, 24, 129.	3.8	15
15	Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution. <i>Cancer Letters</i> , 2019, 440-441, 64-81.	7.2	60
16	Synthesis of New Glycosylated Flavonoids with Inhibitory Activity on Cell Growth. <i>Molecules</i> , 2018, 23, 1093.	3.8	9
17	Suppression of spindly delays mitotic exit and exacerbates cell death response of cancer cells treated with low doses of paclitaxel. <i>Cancer Letters</i> , 2017, 394, 33-42.	7.2	16
18	Spindle Assembly Checkpoint as a Potential Target in Colorectal Cancer: Current Status and Future Perspectives. <i>Clinical Colorectal Cancer</i> , 2017, 16, 1-8.	2.3	16

#	ARTICLE	IF	CITATIONS
19	Prenylated Chalcone 2 Acts as an Antimitotic Agent and Enhances the Chemosensitivity of Tumor Cells to Paclitaxel. <i>Molecules</i> , 2016, 21, 982.	3.8	12
20	Co-silencing of human Bub3 and dynein highlights an antagonistic relationship in regulating kinetochore-microtubule attachments. <i>FEBS Letters</i> , 2015, 589, 3588-3594.	2.8	6
21	Clinicopathologic significance of BubR1 and Mad2 overexpression in oral cancer. <i>Oral Diseases</i> , 2015, 21, 713-720.	3.0	14
22	Targeting the Spindle Assembly Checkpoint for Breast Cancer Treatment. <i>Current Cancer Drug Targets</i> , 2015, 15, 272-281.	1.6	25
23	An Overview of the Spindle Assembly Checkpoint Status in Oral Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	13
24	High CDC20 expression is associated with poor prognosis in oral squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2014, 43, 225-231.	2.7	54
25	Dynein-dependent transport of spindle assembly checkpoint proteins off kinetochores toward spindle poles. <i>FEBS Letters</i> , 2014, 588, 3265-3273.	2.8	34
26	Monitoring the fidelity of mitotic chromosome segregation by the spindle assembly checkpoint. <i>Cell Proliferation</i> , 2011, 44, 391-400.	5.3	62
27	The spindle assembly checkpoint: perspectives in tumorigenesis and cancer therapy. <i>Frontiers in Biology</i> , 2011, 6, 147-155.	0.7	23